Novel activity of acriflavine against colorectal cancer tumor cells |
| |
Authors: | Hassan Saadia Laryea Daniel Mahteme Haile Felth Jenny Fryknäs Mårten Fayad Walid Linder Stig Rickardson Linda Gullbo Joachim Graf Wilhelm Påhlman Lars Glimelius Bengt Larsson Rolf Nygren Peter |
| |
Affiliation: | Department of Medical Sciences, Uppsala University, Uppsala, Sweden. sadia.hassan@medsci.uu.se |
| |
Abstract: | A high-throughput screen of the cytotoxic activity of 2000 molecules from a commercial library in three human colon cancer cell lines and two normal cell types identified the acridine acriflavin to be a colorectal cancer (CRC) active drug. Acriflavine was active in cell spheroids, indicating good drug penetration and activity against hypoxic cells. In a validation step based on primary cultures of patient tumor cells, acriflavine was found to be more active against CRC than ovarian cancer and chronic lymphocytic leukemia. This contrasted to the activity pattern of the CRC active standard drugs 5-fluorouracil, irinotecan and oxaliplatin. Mechanistic studies indicated acriflavine to be a dual topoisomerase I and II inhibitor. In conclusion, the strategy used seems promising for identification of new diagnosis-specific cancer drugs. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|